🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07678697
Recruiting Not applicable

Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique

NCT07678697 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-01
Last updated
2026-07-01

Condition(s) studied

Nd:YAG LaserSclerotherapyDiode LaserReticular VeinsTelangiectasiasCLaCS Technique

Investigational drug(s) / intervention(s)

Nd:YAG laserDiode laser

Nd:YAG laser: Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).

Diode laser: Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).

Study summary

This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18-60 years. * Both sexes. * Presence of reticular veins and/or telangiectasias (CEAP classification C1). * Fitzpatrick skin types II-V. * Patients seeking cosmetic treatment. Exclusion Criteria: * Pregnancy or lactation. * History of deep vein thrombosis. * Coagulation disorders. * Allergy to sclerosant agents. * Active skin infection at treatment site. * Previous treatment of target veins within 6 months. * Great saphenous vein or short saphenous vein incompetence. * Deep venous insufficiency or thrombosis. * Abnormal venous duplex findings.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Cairo Egypt Recruiting

More Ain Shams University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07678697 on ClinicalTrials.gov ↗ ← All trials in Egypt